Healthcare

Truscreen Group has developed a proprietary device designed to provide real-time detection of cervical cell abnormalities, offering an alternative or complement to traditional cervical cancer screening methods such as pap smears and laboratory-based testing. The device is designed to deliver results at the point …

PolyNovo has developed a biodegradable polymer technology, marketed under its NovoSorb brand, used in the treatment of severe wounds, burns, and in reconstructive and hernia repair surgery. The technology functions as a scaffold that supports the body's own tissue regeneration process before gradually being …

Rhythm Biosciences has been developing a blood-based diagnostic test designed to support the detection of colorectal cancer, positioning it as a potential complement or alternative to existing screening methods such as faecal-based tests or colonoscopy. A blood-based approach, if successfully developed and approved, could …

Vitura Health is one of Australia's more established players in the medicinal cannabis space, operating across the value chain from cultivation andManufacturingthrough to distribution and patient access. The company has built a diversified model that includes its own branded cannabis products, a wholesale distributionBusinesssupplying …

Invex Therapeutics Ltd (ASX:IXC) traded at AUD 0.13, gaining 8.33% as attention returned to the company’s latest operating and strategic developments. With a market capitalisation of approximately AUD 9.77M, the stock is up 34.02% over one year. The latest move sits against a broader …

Syntara Ltd (ASX:SNT) traded at AUD 0.026, gaining 8.33% as attention returned to the company’s latest operating and strategic developments. With a market capitalisation of approximately AUD 51.04M, the stock is unchanged over one year. The latest move sits against a broader story shaped …

Radiopharm Theranostics Limited (ASX:RAD) has announced progress in its BetaBart (RV-01) clinical program, with the first patient dosed in the second cohort of its Phase 1/2a clinical trial targeting B7-H3 expressing solid tumours.